Brand Name | Status | Last Update |
---|---|---|
geodon | New Drug Application | 2025-01-13 |
ziprasidone | ANDA | 2025-01-06 |
ziprasidone hydrochloride | ANDA | 2025-04-10 |
ziprasidone mesylate | ANDA | 2025-03-13 |
ziprasidone ziprasidone | ANDA | 2023-08-07 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
tourette syndrome | EFO_0004895 | D005879 | F95.2 |
schizophrenia | EFO_0000692 | D012559 | F20 |
schizophrenia spectrum and other psychotic disorders | — | D019967 | — |
Expiration | Code | ||
---|---|---|---|
ZIPRASIDONE HYDROCHLORIDE, GEODON, VIATRIS | |||
2025-01-28 | M-232 |
Code | Description |
---|---|
J3486 | Injection, ziprasidone mesylate, 10 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Schizophrenia | D012559 | EFO_0000692 | F20 | — | 1 | 13 | 9 | 4 | 27 |
Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 1 | 12 | 1 | 3 | 17 |
Psychotic disorders | D011618 | — | F20.81 | — | 1 | 3 | 8 | 1 | 13 |
Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | 1 | 1 | 1 | 3 |
Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | — | 2 | 1 | 3 |
Mania | D000087122 | — | F30 | — | — | — | 2 | 1 | 3 |
Schizophrenia spectrum and other psychotic disorders | D019967 | — | — | — | — | — | 1 | — | 1 |
Paranoid schizophrenia | D012563 | — | F20.0 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Depression | D003863 | — | F33.9 | — | — | 2 | — | — | 2 |
Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | 1 | — | — | 1 |
Psychomotor agitation | D011595 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Syndrome | D013577 | — | — | — | — | — | — | 1 | 1 |
Psychotic affective disorders | D000341 | — | F39 | — | — | — | — | 1 | 1 |
Drug common name | Ziprasidone |
INN | ziprasidone |
Description | Ziprasidone is a piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms. It has a role as a psychotropic drug, a histamine antagonist, a muscarinic antagonist, a serotonergic antagonist, a dopaminergic antagonist and an antipsychotic agent. It is a member of piperazines, an organochlorine compound, a member of indolones and a 1,2-benzisothiazole. |
Classification | Small molecule |
Drug class | antipsychotic with binding activity on sertonin (5-HT2A) and dopamine (D2) receptors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1 |
PDB | — |
CAS-ID | 146939-27-7 |
RxCUI | — |
ChEMBL ID | CHEMBL708 |
ChEBI ID | 10119 |
PubChem CID | 60854 |
DrugBank | DB00246 |
UNII ID | 6UKA5VEJ6X (ChemIDplus, GSRS) |